One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.

Zavattaro M, Caputo M, Samà MT, Mele C, Chasseur L, Marzullo P, Pagano L, Mauri MG, Ponziani MC, Aimaretti G, Prodam F

Endocrine9 Jan 2015Cited by 41 (Europe PMC)

PMID25572181DOI10.1007/s12020-014-0519-0PepBankPUB-25572181

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12 months of liraglutide reduced fasting plasma glucose irrespective of eGFR category.
In plain wordsIn adults with type 2 diabetes, fasting blood sugar fell after 12 months of liraglutide, whatever the kidney function.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose
Study
n = 84
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
A reduction in fasting plasma glucose (p < 0.01), HbA1c (p < 0.003), BMI (p < 0.01), and systolic (p < 0.01) and diastolic blood pressure (p < 0.006) was recorded irrespective of eGFR category.
2 context sentences(design, population, supporting numbers)
Summary · context
A twelve-month longitudinal prospective post-marketing study was performed.
Summary · context
According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min).
Report a problemFND-2557218101
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12 months of liraglutide reduced HbA1c irrespective of eGFR category.
In plain wordsIn adults with type 2 diabetes, HbA1c fell after 12 months of liraglutide, whatever the kidney function.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n = 84
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
A reduction in fasting plasma glucose (p < 0.01), HbA1c (p < 0.003), BMI (p < 0.01), and systolic (p < 0.01) and diastolic blood pressure (p < 0.006) was recorded irrespective of eGFR category.
2 context sentences(design, population, supporting numbers)
Summary · context
A twelve-month longitudinal prospective post-marketing study was performed.
Summary · context
According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min).
Report a problemFND-2557218102
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12 months of liraglutide reduced BMI irrespective of eGFR category.
In plain wordsIn adults with type 2 diabetes, BMI fell after 12 months of liraglutide, whatever the kidney function.
Peptide
Liraglutide
Outcome
DecreaseBMI
Study
n = 84
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
A reduction in fasting plasma glucose (p < 0.01), HbA1c (p < 0.003), BMI (p < 0.01), and systolic (p < 0.01) and diastolic blood pressure (p < 0.006) was recorded irrespective of eGFR category.
2 context sentences(design, population, supporting numbers)
Summary · context
A twelve-month longitudinal prospective post-marketing study was performed.
Summary · context
According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min).
Report a problemFND-2557218103
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, 12 months of liraglutide reduced systolic and diastolic blood pressure irrespective of eGFR category.
In plain wordsIn adults with type 2 diabetes, blood pressure fell after 12 months of liraglutide, whatever the kidney function.
Peptide
Liraglutide
Outcome
DecreaseSystolic and diastolic blood pressure
Study
n = 84
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
A reduction in fasting plasma glucose (p < 0.01), HbA1c (p < 0.003), BMI (p < 0.01), and systolic (p < 0.01) and diastolic blood pressure (p < 0.006) was recorded irrespective of eGFR category.
2 context sentences(design, population, supporting numbers)
Summary · context
A twelve-month longitudinal prospective post-marketing study was performed.
Summary · context
According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min).
Report a problemFND-2557218104
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, serum creatinine showed only a trend to decrease in both eGFR groups after 12 months of liraglutide.
In plain wordsIn adults with type 2 diabetes, creatinine tended to fall in both groups after liraglutide, without a clear change.
Peptide
Liraglutide
Outcome
No significant changeSerum creatinine
Study
n = 84
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
creatinine levels had a trend to decrease in both groups. eGFR did not change in Group A, while it increased in Group B (p < 0.05) independently from the concomitant changes of other parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
A twelve-month longitudinal prospective post-marketing study was performed.
Summary · context
According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min).
Report a problemFND-2557218105
06HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, total microalbuminuria levels improved in both eGFR groups after 12 months of liraglutide.
In plain wordsIn adults with type 2 diabetes, urine albumin levels improved in both groups after 12 months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseTotal microalbuminuria levels
Study
n = 84
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Total microalbuminuria levels improved in both groups (p < 0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
A twelve-month longitudinal prospective post-marketing study was performed.
Summary · context
According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min).
Report a problemFND-2557218110
07HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and eGFR below 90 ml/min, eGFR increased after 12 months of liraglutide.
In plain wordsIn adults with type 2 diabetes and reduced kidney filtration, eGFR rose after 12 months of liraglutide.
Peptide
Liraglutide
Outcome
IncreaseeGFR in Group B (eGFR below 90 ml/min)
Study
n = 41
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
it increased in Group B (p < 0.05) independently from the concomitant changes of other parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
A twelve-month longitudinal prospective post-marketing study was performed.
Summary · context
According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min).
Report a problemFND-2557218107
08HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and eGFR below 90 ml/min, seven of 41 patients reached normal eGFR values after 12 months of liraglutide.
In plain wordsIn adults with type 2 diabetes and reduced kidney filtration, seven of 41 reached normal eGFR values after liraglutide.
Peptide
Liraglutide
Outcome
IncreaseNormalisation of eGFR in Group B
Study
n = 41
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Moreover, seven out of 41 patients of Group B had increased eGFR levels which reached the normal values (>90 ml/min).
2 context sentences(design, population, supporting numbers)
Summary · context
A twelve-month longitudinal prospective post-marketing study was performed.
Summary · context
According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min).
Report a problemFND-2557218108
09HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, three of five patients with pathological microalbuminuria at baseline returned to normal albuminuria at 12 months of liraglutide.
In plain wordsIn adults with type 2 diabetes, three of five patients with abnormal urine albumin returned to normal after 12 months of liraglutide.
Peptide
Liraglutide
Outcome
DecreaseReturn to normal albuminuria
Study
n = 5
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
At baseline, five patients had pathological microalbuminuria, but at 12 months three of them returned to normal albuminuria (p < 0.006).
2 context sentences(design, population, supporting numbers)
Summary · context
A twelve-month longitudinal prospective post-marketing study was performed.
Summary · context
According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min).
Report a problemFND-2557218109
10HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and eGFR above 90 ml/min, eGFR did not change after 12 months of liraglutide.
In plain wordsIn adults with type 2 diabetes and normal kidney filtration, eGFR did not change after 12 months of liraglutide.
Peptide
Liraglutide
Outcome
No significant changeeGFR in Group A (eGFR above 90 ml/min)
Study
n: not reported in source
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
eGFR did not change in Group A, while it increased in Group B (p < 0.05) independently from the concomitant changes of other parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
A twelve-month longitudinal prospective post-marketing study was performed.
Summary · context
According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI equation, 84 consecutive patients were divided in Group A (eGFR > 90 ml/min) and Group B (eGFR < 90 ml/min).
Report a problemFND-2557218106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.